Medical researchers are not only continuously developing new anti-tumor drugs but are also trying to find new uses for old drugs, hoping to alleviate the suffering caused by cancer and extend survival. High-dose vitamin C treatment for cancer is one of these methods, which is still under research. Many people may wonder how vitamin C, … Read more
To deliver chemotherapy drugs more effectively, small molecule drug conjugates (SMDC), antibody-drug conjugates (ADC), and degrader-antibody conjugates (DAC) have been explored and developed, providing selective delivery while improving the therapeutic index. What are their similarities and differences? What are their respective advantages? What is the current state of research? What does the future hold? This … Read more
Welcome to reprint, please note the source “Jiangcheng ITP Home”🎉🎉🎉 Decitabine (DAC) is commonly known as an anticancer drug, clinically used for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia, chronic myelomonocytic leukemia, and other malignant hematological diseases,because it has demethylation and cytotoxic effects, which can induce cell death. However, its “magical” efficacy in … Read more
Currently, there are 15 ADC drugs approved globally, among which 6 ADC drugs have been approved in China, namely Trastuzumab emtansine, Brentuximab vedotin, Trastuzumab deruxtecan, Vidofludimus, Gemtuzumab ozogamicin, and Sacituzumab govitecan. This article provides a brief summary based on the currently approved ADC drugs worldwide, the types of tumors they are suitable for, and how … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogenic structures without harming normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After … Read more
As of now, the toxicity and prevention measures of ADC in solid tumors are known as follows: â‘ The indications for ADCs are rapidly expanding, gradually shifting from late-stage to early-stage, and from single therapy to combination strategies. â‘¡ The toxicity characteristics of most ADCs are similar to the cytotoxicity of their payloads. â‘¢ Certain … Read more
Last week, while introducing the “Breakthroughs and Innovations in Lung Cancer Treatment” from the “AACR 2021 Annual Report on Anti-Cancer Progress”（>> Click to review）, I mentioned a popular research topic—Antibody-Drug Conjugates (ADCs), which saw two new ADCs approved and two ADCs expanding their indications in 2021. Some readers expressed a desire to learn more about … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies targeting specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the drug payload … Read more
Key Content Preview:In recent years, antibody-drug conjugates (ADCs) have developed rapidly. As of August 2023, there are a total of 15 ADCs on the market globally, with over 1200 drugs under research. In June this year, Nature Biotechnology published a brief report titled “ADCs’ Revival”, highlighting the “breakthrough momentum” of ADCs in new drug development. … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that drugs could be developed to specifically target pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target specificity of monoclonal antibodies with the anti-tumor properties of cytotoxic molecules. After decades … Read more